TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
TELA Bio (NASDAQ: TELA) announced inducement restricted stock unit grants to three newly hired employees totaling 3,600 shares, with a grant date of December 9, 2025. The Compensation Committee approved the awards under the Nasdaq Rule 5635(c)(4) inducement exception as part of each hire's employment compensation.
The restricted stock units vest in equal annual installments over four years, subject to each employee's continued service through applicable vesting dates.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: ELUT and LUNG are up (0.37%, 1.62%), while APYX, ICCM, and XTNT are down (-0.99% to -3.89%). With TELA down 3.42% and no momentum scanner signals, today’s setup appears company-specific rather than a broad Medical Devices sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 19 | Conference participation | Neutral | -8.5% | Announcement of presentation at Piper Sandler healthcare investor conference. |
| Nov 17 | Inducement equity awards | Neutral | +14.1% | Inducement RSUs and stock option grants for new employees under Nasdaq rules. |
| Nov 13 | Equity offering | Negative | -2.6% | Pricing of $13.0M registered direct offering of common stock and pre-funded warrants. |
| Nov 13 | Earnings and financing | Positive | -2.6% | Q3 2025 growth, narrowed losses, and new $70M credit facility announcement. |
| Nov 04 | Earnings date notice | Neutral | -5.8% | Scheduling notice for upcoming Q3 2025 earnings release and conference call. |
Recent TELA headlines have mostly been neutral or financing-related, yet price reactions skew negative, with one positive move on prior inducement grants and a divergence where fundamentally positive Q3 results coincided with a price decline.
Over the last few months, TELA reported Q3 2025 revenue of $20.7M with a 67.5% gross margin and narrowed losses, alongside revised 2025 revenue guidance to at least +16% versus 2024. The company also refinanced and upsized a credit facility up to $70M and completed a $13.0M registered direct offering with common stock and pre-funded warrants. Other updates involved conference participation and prior inducement equity awards under Nasdaq Rule 5635(c)(4). Today’s small RSU inducement grants fit this pattern of ongoing capital structure and HR-related news.
Market Pulse Summary
This announcement details a modest inducement grant of 3,600 restricted stock units to three new employees under Nasdaq Rule 5635(c)(4), vesting over four years. It follows a series of recent financing, earnings, and governance updates. Investors may focus on how ongoing equity awards and earlier capital raises interact with the company’s Q3 2025 growth, narrowed losses, and new credit facility when assessing overall dilution and incentives.
Key Terms
restricted stock units financial
Nasdaq Rule 5635(c)(4) regulatory
AI-generated analysis. Not financial advice.
MALVERN, Pa., Dec. 12, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 3,600 shares of its common stock to three newly-hired employees, with a grant date of December 9, 2025 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio.
The restricted stock units will vest in equal annual installments over four years, subject to each individual's continued service with TELA Bio through the applicable vesting dates.
About TELA Bio, Inc.
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com.
Caution Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA Bio's management. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements. These risks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and TELA Bio assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.
Investor Contact
Louisa Smith
ir@telabio.com